APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for Pancreatic Acinar Cell Carcinoma
Drug: Olaparib
452 locations incl. Anchorage
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04858334·Phase 2·Recruiting